Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Abbott Park, Illinois
- Most recent report
- 8-K, filed Aug 20, 2026
- Incorporated
- Illinois
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 1800
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 33
News 8 of 90
Prospectuses and Registrations 8 of 16
- S-8 Registration statement for an employee plan Apr 24, 2026
- S-8 Registration statement for an employee plan Mar 23, 2026
- 424B5 Prospectus supplement for an offering Feb 25, 2026
- FWP Free writing prospectus Feb 24, 2026
- 424B3 Prospectus supplement for an offering Feb 23, 2026
- S-3ASR Automatic shelf registration Feb 23, 2026
- S-3ASR Automatic shelf registration May 3, 2023
- S-8 Registration statement for an employee plan Dec 14, 2020
Proxies 8 of 25
- DEFA14A Extra proxy material Mar 13, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 13, 2026
- DEFA14A Extra proxy material Mar 14, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 14, 2025
- DEFA14A Extra proxy material Mar 15, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 15, 2024
- PX14A6G Shareholder's own proxy material Apr 10, 2023
- PX14A6G Shareholder's own proxy material Apr 5, 2023
Ownership 8 of 809
- 4 Insider reported a trade Sep 3, 2026
- 4 Insider reported a trade Sep 3, 2026
- 144 Notice of a proposed sale of restricted stock Sep 2, 2026
- 4 Insider reported a trade Aug 27, 2026
- 144 Notice of a proposed sale of restricted stock Aug 25, 2026
- 4 Insider reported a trade Aug 13, 2026
- 144 Notice of a proposed sale of restricted stock Aug 11, 2026
- 4 Insider reported a trade Jul 1, 2026
Other 8 of 27
- 11-K Employee stock plan report Jun 18, 2026
- SD Conflict minerals disclosure May 27, 2026
- ARS Annual report sent to shareholders Mar 13, 2026
- 11-K Employee stock plan report Jun 20, 2025
- SD Conflict minerals disclosure May 29, 2025
- ARS Annual report sent to shareholders Mar 14, 2025
- 11-K Employee stock plan report Jun 25, 2024
- SD Conflict minerals disclosure May 30, 2024
What to read: Jun 2026 10-Q
SECSift found 3 of 8 sections worth reading, with 2 positive, 2 notable, and 6 negative flags.
Full text
Full 10-Q with a $20.6B acquisition, huge debt, earnings halved.Item 2
Acquisition, tax disputes, segment results, liquidity changes all material.PositiveLegal Proceedings (Item 1)
Appeals court affirmed $495M verdict; derivative suit settled. Real legal risk.
What changed: Jun 2026 vs. Mar 2026
About 6% of ABT's Jun 2026 10-Q is new information. 18 paragraphs were added, 90 changed, and 47 removed. Below are the most important lines SECSift identified.
New
- Share repurchases of 11.6M shares for $1.0B in H1 2026; remaining authorization $5.6B (was $6.7B). Item 2
- Exact Sciences contributed $1.0B in sales in H1 2026 (was $96M in Q1 only). Item 2
- OECD released guidance exempting U.S.-parented groups from Pillar 2 minimum tax when enacted. Full text
- Share reserve for future grants jumped to 140 million from 37 million after shareholder approval in April 2026. Full text
Changed
Removed
Everything here comes from Abbott Laboratories's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 19, 2026, from the 10-Q for Jun 2026.